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A B S T R A C T
Objectives: Plasma branched-chain amino acid (BCAA) levels, measured on nuclear magnetic resonance (NMR)
metabolomics research platforms or by mass spectrometry, have been shown to be associated with type 2 dia-
betes mellitus (T2DM) and cardiovascular disease (CVD). We developed a new test for quantiﬁcation of BCAA on
a clinical NMR analyzer and used this test to determine the clinical correlates of BCAA in 2 independent cohorts.
Design and methods: The performance of the NMR-based BCAA assay was evaluated. A method comparison study
was performed with mass spectrometry (LC-MS/MS). Plasma BCAA were measured in the Insulin Resistance
Atherosclerosis Study (IRAS, n= 1209; 376 T2DM subjects) and in a Groningen cohort (n= 123; 67 T2DM
subjects). In addition, carotid intima media thickness (cIMT) was measured successfully in 119 subjects from the
Groningen cohort.
Results: NMR-based BCAA assay results were linear over a range of concentrations. Coeﬃcients of variation for
inter- and intra-assay precision ranged from 1.8–6.0, 1.7–5.4, 4.4–9.1, and 8.8–21.3%, for total BCAA, valine,
leucine, and isoleucine, respectively. BCAA quantiﬁed from the same samples using NMR and LC-MS/MS were
highly correlated (R2=0.97, 0.95 and 0.90 for valine, leucine and isoleucine). In both cohorts total and in-
dividual BCAA were elevated in T2DM (P=0.01 to ≤0.001). Moreover, cIMT was associated with BCAA in-
dependent of age, sex, T2DM and metabolic syndrome (MetS) categorization or alternatively of individual MetS
components.
Conclusions: BCAA levels, measured by NMR in the clinical laboratory, are elevated in T2DM and may be as-
sociated with cIMT, a proxy of subclinical atherosclerosis.
1. Introduction
The branched-chain amino acids (BCAA), valine, leucine and iso-
leucine, are essential amino acids that are not only required for protein
synthesis but have been shown to regulate protein production, protein
degradation and glucose metabolism. Decreased circulating
concentrations of BCAA are associated with several pathological states
including liver disease, early chronic kidney disease and all-cause
mortality [1–4]. Increased BCAA, on the other hand, are associated
with insulin resistance, type 2 diabetes mellitus (T2DM), coronary ar-
tery disease (CAD) and an altered microbiome [3,5–17]. While it has
been hypothesized that increased circulation of BCAA may be a causal
https://doi.org/10.1016/j.clinbiochem.2018.02.001
Received 22 September 2017; Received in revised form 22 December 2017; Accepted 3 February 2018
⁎ Corresponding author at: LabCorp, Morrisville, NC 27616, USA.
1 Contributed equally to the manuscript.
E-mail addresses: wolakdj@labcorp.com (J. Wolak-Dinsmore), e.g.gruppen@umcg.nl (E.G. Gruppen), shalaui@labcorp.com (I. Shalaurova), matyuss@labcorp.com (S.P. Matyus),
grantr@labcorp.com (R.P. Grant), gegenr@labcorp.com (R. Gegen), s.j.l.bakker@umcg.nl (S.J.L. Bakker), otvosj@labcorp.com (J.D. Otvos), connem5@labcorp.com (M.A. Connelly),
r.p.f.dullaart@umcg.nl (R.P.F. Dullaart).
Abbreviations: BCAA, branched chain amino acids; BMI, body mass index; CAD, coronary artery disease; cIMT, carotid intima-medial thickness; CLIA, Clinical Laboratory Improvement
Amendments; CLSI, Clinical and Laboratory Standards Institute; CV%, coeﬃcients of variation; CVD, cardiovascular disease; HDL, high density lipoprotein; LC-MS/MS, liquid chro-
matography coupled to tandem mass spectrometry; LDL, low density lipoprotein; LOB, limit of blank; LOD, limit of detection; LOQ, limit of quantitation; MetS, metabolic syndrome; NMR,
nuclear magnetic resonance spectroscopy; ppm, parts per million; T2DM, type 2 diabetes mellitus; TG, triglycerides
Clinical Biochemistry 54 (2018) 92–99
Available online 09 February 2018
0009-9120/ © 2018 The Authors. Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
factor in the development of insulin resistance and T2DM by con-
tributing to overloading of mitochondria with lipid substrates, leading
to mitochondrial stress and impaired insulin action [3,11], recent ge-
netic evidence supports the concept that insulin resistance may in fact
drive higher circulating fasting BCAA levels [18]. Consistent with these
observations, BCAA may be predictive of diabetes development, and are
responsive to therapeutic interventions that enhance insulin sensitivity
[9,11,13,19,20]. In fact, fasting concentrations of BCAA were found to
be elevated long before the onset of T2DM [9].
Measurement of circulating BCAA may thus be useful for de-
termining early metabolic and organ dysfunction, well in advance of
the development of chronic disease, thereby enabling preventative
measures to potentially ameliorate disease progression. BCAA may also
be useful in biomarker panels for discerning the metabolic pathways
that are altered in individual patients, allowing for personalized treat-
ment paradigms. The aim of the current study was to develop an assay
for determining BCAA concentrations from NMR spectra collected for
routine lipoprotein quantiﬁcation on a clinical laboratory instrument.
For this approach we developed a deconvolution model that takes into
account all possible NMR signals from proteins and lipoprotein particles
that overlap the signals from valine, leucine and isoleucine. With this
newly developed NMR-based assay, we aimed to determine the extent
to which NMR-measured BCAA levels are elevated in T2DM and me-
tabolic syndrome (MetS). We also addressed the association of BCAA
with carotid-intima media thickness (cIMT), a proxy of subclinical
atherosclerosis and a well-established predictor of coronary heart dis-
ease and stroke [21,22].
2. Materials and methods
2.1. Materials and specimen collection
L-Isoleucine, L-leucine and L-valine were purchased from Sigma
Aldrich (St. Louis, MO). Serum pools were prepared by identifying and
pooling serum samples with high and low amino acid ranges from
donor subjects (LabCorp, Morrisville, NC). This study was carried out in
accordance with The Code of Ethics of the World Medical Association
(Declaration of Helsinki), cleared by an Institutional Review Board and
all donors signed consent forms.
2.2. NMR spectra acquisition and BCAA signal deconvolution analysis
NMR spectra were collected on a Vantera Clinical Analyzer
(LabCorp, Raleigh, NC), a fully automated, high-throughput, 400MHz
proton (1H) NMR platform. Serum or plasma samples were prepared on
board the instrument by mixing 1:1 sample:NMR diluent (50mM so-
dium phosphate, 120mM KCl, 5 mM Na2EDTA, 1mM CaCl2, pH 7.4)
and automatically delivered to the ﬂow probe in the spectrometer's
homogeneous magnetic ﬁeld [23]. NMR spectra were acquired in the
same fashion as the NMR LipoProﬁle test [23,24]. Brieﬂy, data acqui-
sition on the Vantera was accomplished with water suppression using
the WET solvent suppression technique [23,24]. The NMR data was
acquired as 3 blocks of 4 scans for a total acquisition time of 48 s.
Spectra were acquired with a sweep width of 4496.4 Hz and 9024 data
points. The data was processed by zeroﬁlling to 32 K points and mul-
tiplied by a Gaussian function to provide resolution enhancement prior
to Fourier Transformation [23,24]. Two levels of controls were in-
cluded at the beginning of each run of test samples for all experiments.
The methyl signals from the three BCAA in the 1H NMR spectrum
produce distinct patterns which can then be used for quantiﬁcation
(Fig. 1). These signals overlap with each other as well as with the
methyl signals from the lipoprotein particles (Fig. 1). Spiking experi-
ments with pure BCAA in serum helped identify the positions of the
signature peaks of valine, leucine and isoleucine (Fig. 1 inset). The
relative positions of the various signature peaks of isoleucine (doublet
and a triplet), leucine (multiplet), and valine (two doublets) are distinct
even within the many NMR signals from the other components in
serum. In addition, experiments with pH titration helped us identify
how these signals move in relation to each other as well as the reference
peak (calcium EDTA). From these experiments we were able to derive
mathematical equations that relate pH to position of the signature
peaks within the NMR spectrum in order to orient the particular pat-
terns of each BCAA so they could then be quantiﬁed individually for
each patient. Therefore, for BCAA analysis, an optimized deconvolution
algorithm was developed which simultaneously mathematically models
the methyl signals from the lipoproteins, proteins and branched chain
amino acids (between 0.718 and 1.02 ppm) in each NMR spectrum and
quantiﬁes valine, leucine and isoleucine. The BCAA concentrations
were determined using non-negative linear least squares by ﬁrst de-
termining the signal areas of their well-characterized distinctive pattern
of peaks and then multiplying by predetermined conversion factors
(units= μM).
2.3. Assay performance testing
A Slide-A-Lyzer Dialysis 10 kDa molecular weight cutoﬀ cassette
(Thermo Scientiﬁc, Rockford, IL) was used to produce serum that was
free of small molecules for determining the limits of blank (LOB). Serum
pools containing low concentrations of valine, leucine or isoleucine (5
pools) were tested to determine the limits of detection (LOD) and
quantitation (LOQ) according to Clinical and Laboratory Standards
Institute (CLSI) guidelines [25] as previously described [23]. Mean
concentration and coeﬃcients of variation (CV%) were calculated for
each pool. Within-run and within-laboratory imprecision were de-
termined based on CLSI guidelines using serum pools targeted at low,
intermediate and high ranges for each of the BCAA [26]. Within-run
(intra-assay) imprecision was determined by analyzing each of the
pools on one day with 20 replicates. The same pools were analyzed for
20 days with two replicates twice per day (total n= 80) to evaluate the
within-laboratory (inter-assay) imprecision. Consistent with CLSI
guidelines [27], linearity was evaluated by comparing known spiked
concentrations of the amino acids with expected concentrations. Line-
arity was tested in duplicate across the biological range from 0 to 600
μM by preparing dialyzed serum samples (as described previously)
spiked with known amino acid concentrations.
2.4. Method comparison
Method comparison studies consistent with CLSI guidelines [28]
were performed to compare BCAA quantiﬁcation by NMR versus mass
spectrometry (MS). Serum specimens were obtained from 21 donors
and aliquots were frozen at−80 °C until the time of analysis. The same
frozen serum samples were analyzed via Liquid Chromatography cou-
pled to tandem mass spectrometry (LC-MS/MS, LabCorp, Burlington,
NC) and NMR (LabCorp, Morrisville, NC). The LC-MS/MS method used
external calibration with stable isotope dilution. Linear regression
analysis and residuals plots were used to evaluate the correlation be-
tween the results from the two platforms.
2.5. Comparison of specimen collection tubes
Blood from 22 donors was drawn into three diﬀerent tubes: Greiner
Bio-One or LipoTube, BD Vacutainer serum tube (red top, no gel bar-
rier) or K2EDTA plasma tube. In order to expand the range of measured
values, 5 specimens with low analyte concentration were diluted
(≤50%) and 4 specimens with elevated analyte were spiked with the
BCAA (≤10% by volume). A total of 31 specimens were tested for each
analyte. Results for red-top serum and EDTA plasma tubes were com-
pared to results for the LipoTube by linear regression and %bias was
calculated.
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2.6. Stability testing
Specimens from 20 donors drawn in LipoTubes were used to assess
specimen/analyte stability. Samples were stored at 4 °C and aliquots
were tested daily or tested after 4months at −80 °C. Mean results for
all donors were evaluated with acceptable diﬀerences falling
within±10% of the day 0 (draw day) mean.
2.7. Cross-sectional studies in patients
2.7.1. Insulin resistance atherosclerosis study (IRAS)
The IRAS recruited 1625 participants from four clinical centers lo-
cated in San Antonio, TX; San Luis Valley, CO; Oakland, CA; and Los
Angeles, CA, between October 1992 and April 1994. Details of the study
population, research methods and exclusion criteria have previously
been published [29]. T2DM was deﬁned as fasting glucose concentra-
tion≥ 7.0 mmol/L and/or 2-h glucose concentration≥ 11.1 mmol/L
by a 75-g oral glucose tolerance test (OGTT) using World Health Or-
ganization criteria [30]. The use of insulin during a 5 year period before
entry was an exclusion criterion. Demographic and socioeconomic in-
formation (e.g., age, sex, ethnicity), as well as lifestyle factors (e.g.,
smoking, alcohol consumption), were collected on standardized ques-
tionnaires by self-report [29,31]. 16% of participants were current
smokers [32]. NMR spectra were acquired in 2000 from fasting plasma
samples collected at baseline (1992–1994) (LipoScience, now LabCorp,
Raleigh, NC) [30,33]. Quantiﬁcation of BCAA was accomplished by
reanalyzing the digitally stored NMR spectra using the newly developed
BCAA software algorithm. The sample size of the current report was
1209 participants after exclusion of subjects with missing NMR data or
diabetes status at baseline. The institutional review boards at each
study site approved the study protocol, and all participants provided
written informed consent.
2.7.2. Groningen cohort
T2DM and non-diabetic subjects, aged> 18 years, participated after
written informed consent had been obtained. T2DM was diagnosed
previously by primary care physicians based established criteria [34].
All participants were white. Insulin use was an exclusion criterion but
the use of antihypertensive medication was allowed. Current smokers
and subjects who used lipid lowering drugs were also excluded, as were
subjects with a history of cardiovascular disease, chronic kidney disease
(estimated glomerular ﬁltration rate < 60mL/min/1.73 m2 and/or
proteinuria), liver function abnormalities or thyroid dysfunction. NMR
spectra were acquired in 2013 from fasting plasma samples collected
between 2003 and 2004. After exclusion of subjects with missing BCAA
results from 123 subjects were analyzed. The study protocol was ap-
proved by the medical ethics committee of the University Medical
Center Groningen, The Netherlands.
2.8. Clinical procedures
Participants were asked to fast for 12 h and to abstain from alcohol
and heavy exercise for 24 h. Body mass index (BMI in kg/m2) was
calculated as weight divided by height squared. Waist circumference
was measured on the bare skin at the natural indentation between the
10th rib and the iliac crest. Blood pressure was measured using a
standard mercury sphygmomanometer after participants were rested
for 5min (IRAS cohort) or 15min (Groningen cohort).
2.9. Laboratory measurements
Venous EDTA-anticoagulated plasma and serum samples were col-
lected after an overnight fast and stored at −80 °C until analysis.
Glucose which was measured shortly after blood sampling using the
glucose oxidase technique on automated instruments (IRAS: Yellow
Springs glucose analyzer; YSI Inc., Yellow Springs, Ohio, USA;
Groningen cohort: APEC glucose analyzer (APEC Inc., Danvers, MA)). In
IRAS, lipids and lipoproteins were analyzed according to Lipid Research
Clinic methodology [31]. In the Groningen cohort, lipids and lipopro-
teins were assayed by routine automated methods as described [34]. In
the Groningen cohort, glycated hemoglobin (HbA1c) was measured by
high performance liquid chromatography (Bio-Rad, Veenendaal, The
Netherlands; normal range 27–43mmol/mol).
2.10. Metabolic syndrome deﬁnition
MetS was deﬁned according to NCEP-ATP III criteria. Three or more
of the following criteria were required for categorization of subjects
with MetS: waist circumference > 102 cm for men and> 88 cm for
women; hypertension (blood pressure≥ 130/85mmHg or use of anti-
hypertensive drugs); fasting plasma triglycerides ≥ 1.70mmol/L; high
density lipoprotein cholesterol (HDL-C)< 1.00mmol/L for men
and< 1.30mmol/L for women; fasting plasma glucose ≥ 5.60mmol/
L.
Fig. 1. NMR signal peaks for the branched chain amino
acids (BCAA) in the NMR LipoProﬁle test spectrum of serum.
The signals from the methyl groups on the BCAA overlap
the signals that arise from the methyl groups on the lipid
molecules contained within lipoprotein particles. Inset:
Larger view of NMR spectra from serum spiked with the
individual BCAA illustrating the relative positions of the
various signature peaks of isoleucine (doublet and a tri-
plet), leucine (multiplet), and valine (two doublets) com-
pared to serum alone. ppm=parts per million.
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2.11. Carotid intima media thickness (cIMT) measurement in the Groningen
cohort
Of the 123 participants, 119 subjects had a successful cIMT mea-
surement. CIMT was measured by ultrasonography in the supine posi-
tion as described [34]. High-resolution B-mode ultrasound images were
scanned (ACUSON 128 XP, Mountain View, CA, USA) with a 7.5MHz
linear array transducer. Three arterial wall segments of each carotid
artery were imaged from a ﬁxed lateral transducer angle at the far wall.
The segments scanned were: the segment 1 cm proximal to the carotid
dilatation (common carotid artery), the segment between the carotid
dilatation and carotid ﬂow divider (carotid bulb) and a 1 cm segment
distal to the ﬂow divider (internal carotid artery). The scans were re-
corded on S-VHS tape and analyzed oﬀ-line by an image analyst who
was unaware of subject's characteristics. B-mode image analyses were
digitized with a frame grabber (DT286 l; Data Translation Inc.; Marl-
boro, MA). The image analysis software was developed using an algo-
rithm as described [21,34]. The mean cIMT of 6 carotid artery segments
was calculated and used for analysis. At a mean cIMT of 0.80mm, inter-
sonographer variability was 0.05mm, with an image analyst varia-
bility < 0.03mm, corresponding to a total coeﬃcient of variation
(CV)< 7.5% [34].
2.12. Statistical analyses
Statistical analyses were performed using JMP version 12.1.0, SAS
v9.4 (SAS Institute, Cary, NC), Analyze-it v3.90.1 (Analyze-it Software,
Ltd., Leeds, UK), SSPS22 or GraphPad Prism 6.0. For the analytical
validation studies, linear regression analyses were performed and
Pearson correlation coeﬃcients were determined for comparisons be-
tween continuous variables. For the epidemiological studies, data are
expressed in mean ± SD (or SEM for ﬁgures) or in median (inter-
quartile range). Skewed variables were natural log (Ln) transformed.
Between-group diﬀerences in continuous variables were determined by
unpaired t-tests. Between-group diﬀerences in dichotomous variables
were determined by χ2-analysis. Multivariable linear regression ana-
lyses were performed to determine the independent associations of
BCAA, valine, leucine and isoleucine with diabetes status and the pre-
sence of MetS, as well as of cIMT with diabetes status, the presence of
MetS, the individual MetS components and the plasma BCAA con-
centration. Two-sided P-values < 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Clinical NMR BCAA assay performance
The NMR signals from the methyl groups on valine, leucine and
isoleucine overlap each other as well as the methyl signals from the
lipid molecules contained within the lipoprotein particles in the typical
NMR LipoProﬁle test spectrum (Fig. 1). Therefore, an assay was de-
veloped that mathematically quantiﬁes each individual BCAA in the
context of each other as well as the lipoprotein concentrations in each
sample (Fig. 1).
In order to show that we were able to accurately quantify individual
BCAA despite the underlying NMR lipid methyl signals, NMR spectra
were obtained from samples tested in the clinical laboratory. The
spectra were analyzed using the BCAA assay (n=3856 samples had
results for both NMR BCAA and chemically-derived triglyceride;
n= 3889 samples had results for both NMR BCAA and chemically-de-
rived total cholesterol). The total cholesterol levels for these samples
varied from 64 to 476mg/dL and the triglyceride levels from 24 to
1153mg/dL. Linear regression analysis was performed and Pearson
correlation coeﬃcients were calculated for the comparison of each
BCAA with triglycerides or total cholesterol. None of the correlation
coeﬃcients reached statistical signiﬁcance (Supplementary Table 2).
The analytical performance of the NMR-based BCAA assay was
evaluated as per CLSI guidelines. The limit of blank (LOB) for valine,
leucine and isoleucine were determined to be 13.9, 25.9 and 3.2 μM,
while the analytical sensitivity or limit of detection (LOD) was calcu-
lated to be 22.6, 37.5 and 12.1 μM. The functional sensitivity or limit of
quantitation (LOQ) for valine, leucine and isoleucine were determined
to be 42.0, 38.0 and 15.0 μM, respectively. The LOQ for all three BCAA
assays was below their reported normal reference intervals. Samples
with three levels of each analyte (low, intermediate and high) were
tested for intra- (within-run) and inter-assay (within-lab) precision. For
total BCAA, valine, leucine, and isoleucine, the CVs for inter-assay and
intra-assay precision were 1.8–6.0, 1.7–5.4, 4.4–9.1, and 8.8–21.3%,
respectively (Table 1).
Linearity was demonstrated between 0 and 600 μM, well above the
normal reference intervals, with correlation coeﬃcients (R2) of 0.99,
1.00 and 1.00 for valine, leucine and isoleucine, respectively
(Supplementary Fig. 1A–C). Based on these data, the measuring or re-
portable ranges for valine, leucine and isoleucine are 42.0–600,
38.0–600 and 15.0–600 μmol/L, respectively.
A method comparison study was performed to compare BCAA
quantiﬁcation by NMR versus LC-MS/MS. Serum BCAA concentrations
quantiﬁed using both platforms correlated well by linear regression
with R2 values of 0.97, 0.95 and 0.90 for valine, leucine and isoleucine,
respectively (data not shown). Deming regression plots revealed R2
values of 0.97, 0.94 and 0.90 for valine, leucine and isoleucine, re-
spectively (Fig. 2A–C). The Bland-Altman plots for all 3 BCAA assays
revealed that the residuals, while randomly dispersed, did show that
there was a systematic bias toward higher results for valine and leucine
and somewhat lower results for isoleucine when quantiﬁed by NMR
compared to the MS assay (Fig. 2D–F).
Three types of specimen collection tubes (LipoTubes, red-top serum
tubes and EDTA plasma tubes) were evaluated for their suitability in the
Table 1
Within-laboratory (inter-assay) and within-run (intra-assay) imprecision for NMR-measured BCAA.
Total BCAA (μM) Valine (μM) Leucine (μM) Isoleucine (μM)
Low Medium High Low Medium High Low Medium High Low Medium High
Within-laba
Mean 260.3 479.1 682.0 129.2 237.8 380.5 115.8 195.9 237.2 34.9 44.0 66.2
SD 15.7 15.5 12.3 5.8 7.4 8.9 9.7 11.6 11.2 7.4 6.2 6.5
CV (%) 6.0 3.2 1.8 4.5 3.1 2.3 8.4 5.9 4.7 21.3 14.1 9.8
Within-runb
Mean 262.4 477.8 681.9 128.0 239.6 381.4 114.7 189.2 229.4 37.0 50.3 62.3
SD 11.5 15.6 14.6 6.9 6.8 6.4 10.4 8.8 10.0 5.8 6.0 5.5
CV (%) 4.4 3.3 2.1 5.4 2.9 1.7 9.1 4.6 4.4 15.8 11.9 8.8
BCAA, branched chain amino acids; CV, coeﬃcients of variation; NMR, nuclear magnetic resonance; SD, standard deviation.
a Based on CLSI EP5-A2 tested using 3 controls, 2 runs per day in duplicate for 20 days (total n= 80).
b Based on 1 run of 20 tests.
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BCAA assay. Duplicate results for 31 specimens were compared be-
tween the various tube types. The results performed on specimens
collected in LipoTubes were plotted against results from the red-top
serum and EDTA plasma tubes and linear regression analyses were
performed. Supplementary Table 1 summarizes the linear regression
characteristics for the tube comparisons. Results indicate that there was
minimal to no (< 5.0%) bias for valine, leucine and isoleucine in plain
serum tubes versus serum collected in LipoTubes. However there were
−6.3% and −13.6% biases for lower results for valine and leucine,
respectively, in the EDTA plasma tubes versus LipoTubes.
The stability of each BCAA was evaluated in twenty serum samples
stored refrigerated (2–8 °C) for up to 13 days or frozen at−80 °C for up
to 4months. Measurements were deemed acceptable if they were
within 10% of the day 0 mean for the each individual analyte. Results
demonstrated that valine and isoleucine were stable at 2–8 °C up to day
12. However, leucine was stable for 1 day at 2–8 °C. All 3 BCAA were
stable when frozen at −80 °C for 4months.
3.2. Relationship of circulating BCAA with T2DM and MetS
In IRAS, T2DM subjects were older compared to non-diabetic sub-
jects (Table 2A). In the Groningen cohort, T2DM subjects were also
older and were more likely to be men (Table 2B). In both cohorts,
systolic blood pressure, BMI and fasting glucose were elevated in T2DM
subjects. Waist circumference was not diﬀerent according to diabetes
status in IRAS but was higher in T2DM subjects in the Groningen co-
hort. In both cohorts, triglycerides were higher and HDL cholesterol
was lower in T2DM subjects. Total cholesterol was lower in T2DM
subjects from the Groningen cohort. In both cohorts, more T2DM sub-
jects fulﬁlled the criteria for MetS (Table 2A and B). In both the IRAS
and Groningen cohorts, total plasma BCAA, as well as valine, leucine
and isoleucine levels separately were elevated in T2DM (all P≤ 0.001)
(Table 2A and B). Total BCAA valine, leucine and isoleucine were also
elevated in subjects with MetS compared to subjects without MetS, with
the exception of leucine in IRAS (data not shown; P < 0.001). They
were also elevated in men compared to women in each cohort (data not
shown; P < 0.001 for each comparison).
Age- and sex-adjusted multivariable linear regression analysis de-
monstrated that total BCAA was found to be independently associated
with diabetes status and the presence of MetS in each cohort (Table 3A
and B). Likewise, valine was independently associated with the pre-
sence of T2DM and MetS. Leucine was independently associated with
diabetes status in IRAS, and was associated with MetS in the Groningen
cohort. Isoleucine was independently associated with T2DM and MetS
in IRAS, and with MetS in the Groningen cohort.
We next evaluated the association between cIMT and BCAA taking
account of diabetes status and MetS categorization in the Groningen
cohort (n=119). In crude analysis, mean cIMT was greater in T2DM
subjects (n=66; 0.884 ± 0.197mm) vs. non-diabetic subjects
(n= 53; 0.788 ± 0.153mm, P=0.005), as well as in subjects with
MetS (n=59; 0.892 ± 0.212mm) vs. subjects without MetS (n= 60;
0.792 ± 0.137mm, P=0.003). In multivariable linear regression
analysis taking account of age, sex, diabetes status and the presence of
MetS, mean cIMT was associated with MetS, but not in the presence
T2DM (Table 4, model 1; R2= 0.306, P < 0.001). In further analysis,
the total BCAA concentration was positively associated with mean
cIMT, independent of age and sex (Table 4, model 2; R2= 0.324,
P < 0.001). Taking account of age and sex the association of cIMT with
the total BCAA concentration remained statistically signiﬁcant after
additional adjustment for the use of sulfonylurea, metformin and an-
tihypertensive medication (cf. Table 4 Model 2: β=0.230, P=0.029;
data not shown). In multivariable analysis now including age, sex,
diabetes status, presence of MetS and BCAA concentration, mean cIMT
was associated with BCAA but not signiﬁcantly with diabetes status and
the presence of MetS (Table 4, model 3; R2= 0.331, P < 0.001). In
alternative analysis including age, sex and the individual MetS
Fig. 2. Deming regression comparison between LC-MS/MS and NMR measured (A) valine, (B) leucine, and (C) isoleucine in serum samples (n=21). Bland-Altman plots for (D) valine,
(E) leucine, and (F) isoleucine assays. The limits of agreement (LoA) are depicted as dotted blue lines and the 0% bias is a solid black line. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
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components the total BCAA concentration was also independently as-
sociated with cIMT (Table 4, model 4; R2= 0.375, P < 0.001).
4. Discussion
Our study is the ﬁrst to show that accurate concentrations of plasma
or serum valine, leucine and isoleucine, can be obtained from the same
NMR spectra that is acquired for determining lipoprotein particle
concentrations on a clinical NMR analyzer, without the need for sup-
pression of the protein and lipoprotein signals [23,24]. Mass spectro-
metric assays have been developed that quantify BCAA both in the
clinical and research settings. Additionally, BCAA concentrations have
been estimated from high-volume NMR metabolomics research plat-
forms where the spectra were collected using conditions in which the
Table 2
Baseline clinical characteristics, metabolic control, plasma lipids and lipoproteins in the Insulin Resistance Atherosclerosis Study (IRAS) (A) and in the Groningen cohort (B).
A IRAS (n= 1209) T2DM subjects (n= 376) Non-diabetic subjects (n=833) P-value
Age (years) 57 ± 8 55 ± 8 <0.0001
Sex, men (%) 180 (48) 358 (43) 0.13
Race
Non-hispanic white (%) 128 (34) 333 (40) 0.04
Hispanic (%) 120 (32) 275 (33) 0.74
African American (%) 128 (34) 225 (27) 0.01
Metabolic syndrome (%) 271 (72) 292 (35) < 0.001
Systolic blood pressure (mmHg) 129 ± 18 122 ± 17 <0.001
Diastolic blood pressure (mmHg) 78 ± 10 78 ± 9 0.31
BMI (kg/m2) 31.5 ± 5.6 28.4 ± 5.6 < 0.001
Waist circumference (cm) 94 ± 14 94 ± 13 0.43
Glucose (mmol/L) 9.8 ± 3.3 5.5 ± 0.6 < 0.001
Total cholesterol (mmol/L) 5.51 ± 1.12 5.45 ± 1.11 0.44
HDL-C (mmol/L) 1.05 ± 0.30 1.21 ± 0.39 < 0.001
Triglycerides (mmol/L) 1.77 (1.19–2.46) 1.24 (0.88–1.81) < 0.001
Total BCAA (μM) 393 ± 77 337 ± 73 <0.001
Valine (μM) 241 ± 41 210 ± 39 <0.001
Leucine (μM) 102 ± 34 89 ± 32 <0.001
Isoleucine (μM) 50 ± 19 39 ± 16 <0.001
B Groningen cohort (n= 123) T2DM subjects (n=67) Non-diabetic subjects (n= 56) P-value
Age (years) 59 ± 9 54 ± 10 0.003
Sex (men/women) 41/26 23/33 0.041
Metabolic syndrome (%) 48 (72) 12 (21) <0.001
Systolic blood pressure (mmHg) 145 ± 20 130 ± 20 <0.001
Diastolic blood pressure (mmHg) 87 ± 9 82 ± 12 <0.001
BMI (kg/m2) 29.0 ± 4.9 25.7 ± 4.1 <0.001
Waist circumference (cm) 102 ± 13 87 ± 13 <0.001
Glucose (mmol/L) 8.9 ± 2.3 5.6 ± 0.6 <0.001
HbA1c (mmol/mol) 50 ± 7 34 ± 3 <0.001
Total cholesterol (mmol/L) 5.34 ± 0.91 5.77 ± 0.97 0.014
HDL-C (mmol/L) 1.29 ± 0.39 1.54 ± 0.41 0.001
Triglycerides (mmol/L) 1.76 (1.20–2.17) 1.34 (0.88–1.91) 0.054
Total BCAA (μM) 499 ± 95 401 ± 87 <0.001
Valine (μM) 278 ± 44 219 ± 41 <0.001
Leucine (μM) 162 ± 37 139 ± 37 0.001
Isoleucine (μM) 59 ± 25 43 ± 19 <0.001
Data in means ± SD or in medians (interquartile ranges). BCAA, branched chain amino acids; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; T2DM, type 2 diabetes
mellitus.
Table 3
Multivariable linear regression analysis demonstrating associations of plasma total BCAA, valine, leucine and isoleucine with T2DM and MetS in the Insulin Resistance Atherosclerosis
Study (IRAS) (A) and in the Groningen cohort (B).
BCAA Valine Leucine Isoleucine
β P-value β P-value β P-value β P-value
A IRAS (n= 1209)
Age −0.015 <0.001 −0.016 < 0.001 −0.012 0.0003 −0.007 0.030
Sex (men/women) 0.570 <0.001 0.560 < 0.001 0.404 < 0.0001 0.425 < 0.001
T2DM (yes/no) 0.604 <0.001 0.600 < 0.001 0.382 < 0.0001 0.517 < 0.001
MetS (yes/no) 0.297 <0.001 0.384 < 0.001 0.037 0.53 0.323 < 0.001
B Groningen cohort (n= 123)
Age −0.038 0.60 −0.020 0.77 0.014 0.86 −0.139 0.097
Sex (men/women) 0.353 <0.001 0.295 < 0.001 0.380 < 0.001 0.273 0.001
T2DM (yes/no) 0.216 0.010 0.349 < 0.001 0.011 0.90 0.159 0.099
MetS (yes/no) 0.395 <0.001 0.339 < 0.001 0.409 < 0.001 0.314 0.001
β: standardized regression coeﬃcient. All analyses are adjusted for age and sex. The data from IRAS are also adjusted for race. BCAA, branched chain amino acids; MetS, metabolic
syndrome; T2DM, type 2 diabetes mellitus.
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NMR signals from the proteins and lipoproteins were suppressed; often
called Car-Purcell-Meiboom-Gill (CPMG) or low-molecular-weight me-
tabolites (LMWM) spectra [7,12,35]. The strength of the NMR meta-
bolomics research platform lies in its ability to simultaneously inter-
rogate disease associations for a large number of metabolites, as well as
to assess overall metabolic health in epidemiological studies [7,12,35].
As proposed recently, however, the NMR metabolomics applications,
where the spectral data in its entirety is used as the basis for multi-
variate statistical analyses, are unlikely to provide a reliable basis for
providing individual test results in the clinical laboratory setting [36].
In contrast, our deconvolution based NMR assay quantiﬁes BCAA in
serum or plasma while taking into account the overlapping signals from
the proteins and lipoproteins in each sample, thereby allowing quan-
tiﬁcation from spectra collected for other clinical purposes, for example
quantiﬁcation of LDL particle number (LDL-P) for management of
cardiovascular risk or GlycA for cardiovascular risk assessment [23,37].
Similar to the LDL-P and GlycA tests, the BCAA assay is high-
throughput. The time for the assay is only 90 s and there is no need for
sample preparation before placing it on the clinical instrument for
analysis. With that said, we acknowledge that the %CV for isoleucine,
for example, is fairly high because we have sacriﬁced sensitivity to
detect small molecule analytes that circulate at relatively lower con-
centrations in order to quantify them from spectra that include NMR
signals from proteins and lipoproteins. Nonetheless, the analytical
performance data revealed that the BCAA assay is robust and suitable
for clinical testing. In addition, serum levels of valine, isoleucine and
leucine, quantiﬁed by NMR, were highly correlated to those measured
by mass spectrometry, a platform that is highly sensitive and speciﬁc.
Therefore, BCAA concentrations obtained using the here described
NMR method may be useful for clinical purposes.
Because this assay is novel, we sought to determine if BCAA levels,
measured in this way, were associated with clinical outcomes.
Consistent with recent literature, analysis from 2 independent cohorts
showed that NMR-measured total BCAA, valine, leucine and isoleucine
are elevated in subjects with T2DM compared to non-diabetic subjects
[3,5–13]. In further analysis total BCAA were independently and po-
sitively associated with T2DM and MetS in each cohort. In line, we
recently reported that in subjects with varying degrees of glucose tol-
erance, NMR BCAA levels are closely related to insulin resistance, as
assessed by homeostasis model assessment [17]. Although in a small
number of participants, our current study also suggested that total
BCAA may be directly related to cIMT as a proxy of subclinical ather-
osclerosis, independent of the presence of T2DM, MetS or its individual
components [3,4,10,16]. Though preliminary, this cross-sectional
association adds to recent observations showing that BCAA predict in-
cident CVD, in particular stroke [14,16]. Potential mechanisms leading
to alterations in circulating BCAA concentrations include excess dietary
consumption, increased production by gut microbes, elevated protein
degradation and decreased BCAA catabolism in muscle and adipose
tissue, due to reduced expression of genes involved in the BCAA cata-
bolic pathway [3,11,15].
Given that BCAA may predict T2DM, BCAA measurement could be
useful for determining early metabolic dysfunction, well in advance of
the development of chronic disease, thereby enabling preventative
measures to potentially reduce disease progression [14,38,39]. To this
end, NMR spectroscopy-measured valine, incorporated into a multi-
marker algorithm, was able to contribute to the prediction of future
T2DM [40]. Individual or total BCAA may also be useful in biomarker
panels for discerning the metabolic pathways that are altered in speciﬁc
patient categories, allowing for personalized treatment paradigms.
While NMR technology is not prevalent in most clinical laboratories to
date, it is available for clinical sample testing in one of the largest
clinical laboratories in the US and is becoming more widely available
with the dissemination of NMR instruments in multiple laboratories
across North America and Europe.
Several methodological issues regarding the present study should be
acknowledged. We consider it a strength that the association of total
BCAA with T2DM was documented in 2 separate cohorts, i.e. IRAS
comprising multiethnic individuals and the Groningen study which was
carried out among white subjects from north European descent.
Obviously, the cross-sectional design of these studies does neither allow
us to address the nature of the observed relationships, nor to exclude
the possibility of reverse causation. Thus, it remains possible that BCAA
may be elevated as a consequence of metabolic alterations leading to
T2DM. Furthermore, subjects using insulin did not participate in either
study, making it likely that subjects without severe hyperglycemia were
preferentially included. While this may to some extent limit general-
izability of our ﬁndings, it seems plausible that the absence of insulin
using T2DM subjects in our study populations could have resulted in
some underestimation with respect to the extent to which elevated
BCAA levels are associated with dysglycemia. Finally, in the age- and
ex-adjusted multivariable linear regression analysis regarding the in-
dependent association of cIMT with BCAA we included both the pre-
sence of T2DM and MetS and in alternative analysis the individual MetS
components. In each analysis, the total BCAA concentration was asso-
ciated with cIMT.
In conclusion, BCAA levels can be obtained with suﬃcient precision
and accuracy from the same NMR spectra acquired for lipoprotein
Table 4
Multivariable linear regression analysis demonstrating the association of mean carotid intima media thickness with diabetes status, presence of MetS and plasma branched chain amino
acid (BCAA) concentration in the Groningen cohort (119 subjects; 66 subjects with T2DM and in 53 subjects without T2DM; 59 subjects with MetS and 60 subjects without MetS).
Model 1 Model 2 Model 3 Model 4
β P-value β P-value β P-value β P-value
Age 0.387 <0.001 0.404 < 0.001 0.395 <0.001 0.314 < 0.001
Sex (men vs. women) 0.232 <0.001 0.129 0.13 0.154 0.084 0.144 0.098
T2DM (yes/no) 0.020 0.83 −0.025 0.79
MetS (yes/no) 0.193 0.035 0.107 0.27
Elevated glucose 0.041 0.62
Elevated blood pressure 0.200 0.019
Enlarged waist 0.039 0.67
Elevated triglycerides 0.055 0.62
low HDL cholesterol −0.135 0.12
BCAA 0.263 0.002 0.212 0.043 0.217 0.038
β: standardized regression coeﬃcient. BCAA, branched chain amino acids; cIMT, carotid intima-media thickness; HDL, high density lipoproteins; MetS, metabolic syndrome; T2DM, type
2 diabetes mellitus.
Model 1: adjusted for age, sex, diabetes status and the presence of MetS (R2= 0.306).
Model 2: adjusted for age, sex and BCAA concentration (R2= 0.324).
Model 3: adjusted for age, sex, diabetes status, the presence of MetS and BCAA concentration (R2=0.331).
Model 4: adjusted for age, sex, diabetes status, individual MetS components and BCAA concentration (R2= 0.375).
J. Wolak-Dinsmore et al. Clinical Biochemistry 54 (2018) 92–99
98
particle concentrations and the GlycA test. NMR-measured BCAA are
elevated in MetS and T2DM, and associate with cIMT. Although clinical
utility for a standalone BCAA assay has not been established, BCAA
quantiﬁcation in conjunction with other well established markers may
be useful for disease detection and prediction, as well as for monitoring
disease progression and treatment.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.clinbiochem.2018.02.001.
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